Kamada Reports Top-line Results From Phase 1/2 Trial Of IgG Treatment For COVID-19

Kamada Ltd. (KMDA) reported top-line results from its phase 1/2 open-label, single-arm, multi-center clinical trial in Israel of the company's anti-SARS-CoV-2 plasma-derived hyperimmune globulin treatment for COVID-19. In January 2021, the Israeli Ministry of Health started the study of Kamada's COVID-19 IgG product.

The trial assessed the safety, anti-SARS-CoV-2 IgG levels, virus neutralization activity and other exploratory efficacy outcomes in hospitalized, non-ventilated COVID-19 patients with pneumonia. 11 of the 12 patients recovered following treatment. The anti-SARS CoV-2 IgG levels in the plasma of all patients increased. The IgG product showed a favorable safety profile, the company said.

The company noted that the effect of the treatment on neutralization activity is being further analyzed, however, preliminary results showed that the IgG level increase was associated with enhanced neutralization activity.

"We believe the top-line results of our Phase 1/2 study are indicative of the potential of our plasma-derived IgG product to be a safe and effective treatment for hospitalized COVID-19 patients," said Amir London, Kamada's CEO.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT